01:27

Harnessing resilience mechanisms to prevent neuronal loss in Alzheimer's disease

01:37

The impact of meditation on mental health and well-being in aging

01:33

Introducing novel AD biomarkers into clinical practice: how close are we?

02:20

How society needs to be made ready to treat Alzheimer’s disease

01:25

Inspiring advances in research through scientific meetings

02:18

The potential of brain-derived tau as a neurodegeneration biomarker

01:47

Metabolome-wide association studies in Alzheimer's disease

01:00

Interactions between Aβ and tau proteins in Alzheimer’s disease

03:05

Sex differences in Alzheimer's disease plasma biomarkers

02:27

Polygenic risk scores for Alzheimer's disease in relation to cognitive change

01:47

Tau-targeted therapy landscape in Alzheimer’s disease

01:46

Next steps in anti-amyloid immunotherapy

01:24

Markers of of tau pathology in Alzheimer’s disease

02:41

Updates on tau topography and propagation

06:52

Metabolomics analysis of the FINGER trial

01:46

The direction of disease-modifying therapeutic development in Alzheimer’s disease

04:48

Subtyping mixed primary progressive aphasia

02:24

Shaping future care: biomarker advances in Alzheimer’s Disease

01:44

Challenges in fluid biomarker development in Alzheimer's disease research

01:13

Neuroprotective effects of transcription factor NRF2 in Alzheimer’s disease mice models

03:09

How are blood-based biomarkers currently used in Alzheimer’s disease?

01:12

ALZ-801 in combination with anti-amyloid antibodies for the treatment of Alzheimer’s disease

02:39

Distinguishing between late-onset primary psychiatric disorders and dementia

01:45

Promise of tau-PET imaging for Alzheimer's disease

04:22

Prognostic accuracy of plasma NfL to predict Alzheimer’s disease dementia

01:01

Neuroimaging and fluid biomarkers in early-onset Alzheimer’s disease

01:34

Prognostic value of plasma biomarkers GFAP and pTau181 for all-cause and Alzheimer’s dementia

05:19

Examining plasma vs. CSF p-tau217 in preclinical and prodromal Alzheimer’s disease

03:07

How goes audiovisual gamma stimulation provide benefit in Alzheimer's disease?

01:33

BACE1 inhibitors: investigating the mechanisms of cognitive worsening

01:15

Evolving use of tau-specific fluid biomarkers for Alzheimer's disease

01:53

LEADS: shedding light on early-onset Alzheimer's disease

01:36

The challenges of using animal models in Alzheimer’s research

05:15

Diagnostic performance of plasma p-tau217 in a memory clinic cohort

03:31

ALZ-801 Phase II data & launch of Phase III study in early Alzheimer’s disease

00:54

The preventative potential of gamma frequency stimulation for preclinical Alzheimer’s disease

01:43

Exploring the cognitive impact of BACE1 inhibition for Alzheimer’s disease

00:51

Will blood-based biomarkers replace PET for trial recruitment?

08:35

Using machine learning to predict progression from subject cognitive decline to Alzheimer’s disease

04:19

Current projects from Alzheimer’s Disease International

01:24

Digital frailty screening in dementia

00:50

Will long-term anti-amyloid treatment show greater clinical benefit?

02:33

Anti-amyloid therapy for Alzheimer's disease: beyond the 18-month mark

04:44

Influence of genetic risk for psychiatric disorders on dementia

04:12

Updates in Alzheimer’s treatment: the potential of NSC001

03:58

Promising FONLISA test for ultrasensitive detection of plasma NfL in Alzheimer’s disease

01:20

The importance of a timely diagnosis for cognitive decline

04:28

Most patients excluded from using current anti-amyloid therapies in Alzheimer’s disease

04:13

Therapeutics for AD: addressing the lack of affordability

02:06

The role of governments in addressing the access issues to dementia treatment

02:31

Barriers to dementia treatment: awareness, accessibility, and affordability

05:30

Insights into the use of PROTACs in Alzheimer’s disease

02:06

The potential of ALZ-801 as an oral small molecule treatment for Alzheimer’s disease

04:41

Insights into cellular signatures of cognitive resilience

02:39

Investigating p-tau217 as a clinical screening tool

06:03

Gamma frequency stimulation as a treatment for Alzheimer’s disease

02:35

Revisiting BACE inhibitors: the potential of BACE1 for delaying Alzheimer’s onset

04:20

Quantifying tau pathology patterns in young-onset Alzheimer’s disease

04:55

Enhancing trials to prove disease modification in early Alzheimer's disease

01:37

Recommendations for the deployment of second-generation memory clinics